4.23

7.24% -0.33

Pre-market: 4.24 0.010 +0.24%

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $4.23, with a volume of 1.07M. It is down -7.24% in the last 24 hours and up +24.05% over the past month. Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Previous Close:

$4.56

Open:

$4.53

24h Volume:

1.07M

Relative Volume:

0.54

Market Cap:

$281.40M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-4.5484

EPS:

-0.93

Net Cash Flow:

$-31.47M

1W Performance:

-0.24%

1M Performance:

+24.05%

6M Performance:

+76.99%

1Y Performance:

+153.29%

1-Day Range:

$4.16

$4.60

1-Week Range:

$4.12

$4.99

52-Week Range:

$1.66

$6.42

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1167)

Industry

Biotechnology (674)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-10-31

Latest SEC Filings

CRDF's Discussions on Twitter

Compare CRDF with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDF Cardiff Oncology Inc	4.23	281.40M	488.00K	-41.44M	-31.47M	-0.93
VRTX Vertex Pharmaceuticals Inc	480.35	123.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	723.47	79.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.94	37.97B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.20	31.74B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	259.70	27.71B	3.32B	-860.46M	-1.04B	-8.32

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-06-24	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

View All

Cardiff Oncology Inc Stock (CRDF) Latest News

Feb 25, 2025

Cardiff Oncology Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

Feb 25, 2025

Feb 24, 2025

Cardiff Oncology to Present at Upcoming Investor Conferences - The Manila Times

Feb 24, 2025

Can Cardiff Oncology's New Colorectal Cancer Approach Transform Treatment? CEO to Reveal Strategy - StockTitan

Feb 24, 2025

Feb 23, 2025

Critical Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Vir Biotechnology (NASDAQ:VIR) - Defense World

Feb 23, 2025

Feb 22, 2025

Cardiff Oncology (CRDF) to Release Earnings on Thursday - Defense World

Feb 22, 2025

Feb 20, 2025

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - The Manila Times

Feb 20, 2025

Can Cardiff Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan

Feb 20, 2025

Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m - Simply Wall St

Feb 20, 2025

Feb 19, 2025

Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short Interest - MarketBeat

Feb 19, 2025

Taking on analysts’ expectations and winning: Cardiff Oncology Inc (CRDF) - SETE News

Feb 19, 2025

Feb 18, 2025

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib (NASDAQ:CRDF) - Seeking Alpha

Feb 18, 2025

Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Increase in Short Interest - Defense World

Feb 18, 2025

Feb 14, 2025

SG Americas Securities LLC Sells 6,103 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Feb 14, 2025

Feb 13, 2025

Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World

Feb 13, 2025

Feb 12, 2025